Literature DB >> 926457

Effects of ID-540 on averaged photopalpebral reflex in man.

M Tanaka, H Isozaki, K Inanaga.   

Abstract

Effects of ID-540, a recently introduced benzodiazepine derivative, on the averaged photopalpebral reflex (PPR), subjective symptoms and serum levels of ID-540 and its principal metabolite, N-desmethyl-ID-540 following an oral dose of 0.5 mg were investigated in 4 healthy male Japanese students in their early twenties. Both the latencies of PPR, P1 and P2 latency, showed a prolongation and maximum level at 2-2.5 hours after administration and tended to decline thereafter to control levels. The serum concentration of ID-540 showed a peak level at 2 hours after dosing, then showed a decline at 4 hours. The N-desmethyl-ID-540 exhibited a slow, gradual rise in the serum over the first 4 hours and there was a tendency toward a continued rise even at 24 hours. These parameters were of striking resemblance in the time-course of changes after oral dosing. Thus the PPR test may be a useful means of determining the clinical effects of anxiolytic agents. ID-540 appears to be an agent with remarkable anxiolytic effects.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 926457     DOI: 10.1254/jjp.27.517

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  3 in total

1.  The effects of a new benzodiazepine derivative, ID-540, on the averaged photopalpebral reflex in man.

Authors:  M Tanaka; H Isozaki; K Inanaga; N Ogawa
Journal:  Psychopharmacology (Berl)       Date:  1978-07-19       Impact factor: 4.530

2.  Effect of brotizolam on the averaged photopalpebral reflex in man.

Authors:  M Tanaka; H Isozaki; Y Mizuki; K Inanaga
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

3.  Effect of zopiclone on the arousal level of healthy volunteers assessed by the averaged photopalpebral reflex.

Authors:  M Tanaka; Y Mizuki; H Isozaki; K Inanaga
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.